Zhitong Finance App News, Shanghai Pharmaceutical (02607.HK) announced that recently, Shanghai Hefeng Pharmaceutical Co., Ltd. (hereinafter referred to as “Shangyao Hefeng”) received the “Drug Supplement Application Approval Notice” (Notice Number: 2026B05944) issued by the State Drug Administration for lincomycin hydrochloride injections. The drug passed the generic drug consistency evaluation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.